Andrea has over 20 years of leadership and program management experience in the healthcare and med tech innovation space. In addition to an MBA and MPH from Columbia University, she has extensive experience supporting early stage ventures bringing products to market.
Andrea is deeply committed and passionate about leading the amazing East River BioSolutions team as it leverages its proprietary platform to create novel tissue‐specific extracellular matrix biomaterials capable of bridging the multi-billion-dollar gap between in vitro and in vivo research.
Dr. O’Neill is a post-doctoral scientist in Biomedical Engineering at Columbia University. His work is focused on cell and tissue engineering, the innovation and development of therapeutic extracellular matrix biomaterials, and novel extracorporeal organ support systems for organ transplantation.
He received his PhD in Biomedical Engineering from Columbia University and BS in Physics from the University of California at Santa Barbara.
Dr. Vunjak-Novakovic is the Mikati Foundation Professor of Biomedical Engineering and University Professor of Medical Sciences at Columbia University, where she directs the Laboratory for Stem Cells and Tissue Engineering.
Her research focuses on engineering human tissues for regenerative medicine, stem cell research, and modeling disease. Extensively published and highly cited (18,500 citations and h=82 on the ISI Web of Science; >31,000 citations and h=101 on Google Scholar), she has 76 licensed, issued or pending patents and has founded three biotech companies – epiBone, Tara Biosystems, and East River BioSolutions.
She is a frequent advisor to government and industry and is a member of the American Institute for Medical and Biological Engineering, Academia Europaea, National Academy of Engineering, National Academy of Medicine, and National Academy of Inventors.
Mr. Greenfield is a serial entrepreneur who has been involved in launching and advancing several biotech companies. Currently, Mr. Greenfield is the executive v.p. of business development and a director for AZ Therapies, a company in a Pivitol Phase III trial for prolonging or halting the progression of alzheimers disease with promise in several other neurodegenerative disorders including Ischemic Stroke, ALS, Parkinsons and concussion. Mr Greenfield was a co-founder of Genuine Health International a company that owns supplement brands in Canada and the US. Mr. Greenfield serves as director for AAVP Biosystems a company developing a targeted gene delivery vector that aims to direct therapy to tumor cells with a platform exclusively licensed out of MD Anderson Cancer Center. Mr. Greenfield is the President and founder of The Dover Group, a financial services provider that caters to high net worth families and family offices. Mr Greenfield leads the insurance and estate planning departments. Previously, Mr. Greenfield was a founder of Imaging Biopharmaceutical and Zebra Pharmaceutical which later merged into Biostream prior to going public as Molecular Insight. Most recently, Mr. Greenfield was a co-founder and director at IQuum, Inc., a medical diagnostic company that was sold to Roche in 2014 for $485 million. Mr Greenfield along with his wife Tina and their four children founded Open Fields a non-profit children’s theater program in 1999 and Brave Arts summer program in 2008.
Anthony is a seasoned business executive and entrepreneur, with over 25 years of experience in life sciences, technology, & finance. Currently, he is the CEO of Immplacate, Inc. an emerging biotechnology firm involved in cell therapies related to immune disorders. He has held various senior level positions with global responsibilities, which include medical device powerhouse Guidant, where he was involved in various aspects of the cardiovascular portfolio of products. He has specialized capabilities in sales, marketing, finance, operations, HR, R&D, and strategy. Anthony holds an MBA from Columbia Business School, Columbia University in New York.
Mr. King has been investing in wellness, healthcare, and consumer products businesses in North America and Asia since 1999. He is Chair of the Board of Genuine Health International, which owns natural supplement brands in the United States, Canada, and the People’s Republic of China. Mr. King is also Co-chairman of the Advisory Board at AZTherapies, which is developing innovative treatments for Alzheimer’s disease, stroke, and amyotrophic lateral sclerosis (ALS). He is a Co-founder and partner of Shanghai-based Peak China Advisors and Taipei-based Peak Capital, which advises wellness and consumer-related companies across Greater China. Previously, Mr. King was Co-founder and President of GNC China, and a Co-founder and Director of Prestige Brands, which acquired multiple brands including Chloraseptic, Comet, Murine, Clear Eyes, and Prell Shampoo. From 1983 – 1999, he was an investment banker at PaineWebber, and served as the Chairman of PaineWebber’s Asia businesses. Mr. King graduated with honors from Yale University.
Dr. Bacchetta is an Associate Professor of Cardiothoracic Surgery, the Surgical Director of the Pulmonary Hypertension Comprehensive Care Center, the Surgical Director of the Adult Extracorporeal Membrane Oxygenation Program, and the Director of the Pulmonary Thromboendarterectomy Program at Columbia University Medical Center–New York Presbyterian Hospital.
His background in engineering, thoracic surgery, and business has helped to establish him as a leading innovator in the biomedical field.
He received his MD from Weill Medical College of Cornell University and completed his Thoracic Surgery Fellowship at Columbia University Medical Center.
Dr. Elmaleh is an Associate Professor at Harvard Medical School and the Director of Contrast Media Chemistry at Massachusetts General Hospital. He is also the Founder, President, and Chairman of the Board of AZTherapies.
A renowned molecular imaging expert and inventor of numerous molecular imaging agents (including three drugs that are in use in man or at late stage clinical trials), he is the recipient of numerous NIH and DOE grant awards, a co-author of over 130 publications and book chapters, and an inventor of over 80 issued and pending patents in a range of disciplines, including molecular imaging and pharmaceuticals.
Dr. Elmaleh is a founder of several biotech companies including Molecular Insight (formerly Biostream), Mersana (formerly NanoPharma) that recently closed a drug deal for $700M with Teva, and FluoroPharma Medical. He also co-founded PureTech Health (formerly PureTech Ventures) and holds a BSc in Physics and Chemistry and an MS and PhD in Organic Chemistry from Hebrew University of Jerusalem.
Ms. Bruggemann’s career has spanned over 20 years in Corporate Finance and Operations including Controlling, Financial Planning and Analysis, Commercial Finance and Operations Finance across various industries. She began her career as a process design and startup engineer for petrochemical and gas purification applications.
Ms. Bruggemann received her BE in Chemical Engineering from Manhattan College and her MBA in Finance and International Business from New York University Leonard N. Stern School of Business.
Director of Product Management and Business Development
Tanya has over 10 years of experience working in the biotech industry. Tanya received her MS in Biotechnology Engineering from Technical University of Denmark and MBA from Kellstadt Graduate School of Business, Chicago.
Tanya has spent the last decade working in a variety of roles that include Consulting, Business Development, and Marketing.
Dr. Germanguz is a stem cell biologist with more than 10 years of experience studying pluripotent stem cells. His research was focused on understanding various mechanisms which regulate cell fate decisions, differentiation and reprogramming.
He received his PhD in Medical Science from the Technion (Israel) under the supervision of Prof. Itskovitz-Eldor and his postdoctoral training in Prof. Bill Lowry’s lab at UCLA
Jennifer became interested in scientific research in high school while studying oral pathogens at University of Kentucky and earned her bachelor’s degree in Biomedical Engineering from Columbia University.
Within those years, she has been a member of biology, biomedical engineering, and chemical engineering labs.
When she’s not doing science, she’s attending dance classes, exploring the city, or playing fetch with her cat.
Emma earned a BA in Organismal Biology from Vanderbilt University, and she has worked in translational science research at both University of Rochester and Columbia University. She helped found East River Biosolutions to bring much-needed tissue specific biomaterials to both basic science and translational medicine.
Emma is currently pursuing an MD from New York University, and will be pursuing a residency in Internal Medicine.